User login
Effectiveness of Rosiglitazone and Pioglitazone to Reduce Hemoglobin A1c Levels in Veteran Patients With Type 2 Diabetes
Article Type
Changed
Display Headline
Effectiveness of Rosiglitazone and Pioglitazone to Reduce Hemoglobin A1c Levels in Veteran Patients With Type 2 Diabetes
Article PDF
Issue
Federal Practitioner - 27(10)
Publications
Topics
Page Number
22
Legacy Keywords
diabetes, hemoglobin A1c, HbA1c, therapeutic agents, thiazolidinediones, TZD, FDA, rosiglitazone, pioglitazone, Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes, sulfonylureas, insulindiabetes, hemoglobin A1c, HbA1c, therapeutic agents, thiazolidinediones, TZD, FDA, rosiglitazone, pioglitazone, Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes, sulfonylureas, insulin
Sections
Article PDF
Article PDF
Issue
Federal Practitioner - 27(10)
Issue
Federal Practitioner - 27(10)
Page Number
22
Page Number
22
Publications
Publications
Topics
Article Type
Display Headline
Effectiveness of Rosiglitazone and Pioglitazone to Reduce Hemoglobin A1c Levels in Veteran Patients With Type 2 Diabetes
Display Headline
Effectiveness of Rosiglitazone and Pioglitazone to Reduce Hemoglobin A1c Levels in Veteran Patients With Type 2 Diabetes
Legacy Keywords
diabetes, hemoglobin A1c, HbA1c, therapeutic agents, thiazolidinediones, TZD, FDA, rosiglitazone, pioglitazone, Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes, sulfonylureas, insulindiabetes, hemoglobin A1c, HbA1c, therapeutic agents, thiazolidinediones, TZD, FDA, rosiglitazone, pioglitazone, Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes, sulfonylureas, insulin
Legacy Keywords
diabetes, hemoglobin A1c, HbA1c, therapeutic agents, thiazolidinediones, TZD, FDA, rosiglitazone, pioglitazone, Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes, sulfonylureas, insulindiabetes, hemoglobin A1c, HbA1c, therapeutic agents, thiazolidinediones, TZD, FDA, rosiglitazone, pioglitazone, Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes, sulfonylureas, insulin
Sections
Article Source
PURLs Copyright
Inside the Article
Article PDF Media
Document